Translational Research
Rarecells is conducting a clinical study to assess the sensitivity of its new CTC-DNA technology in early stage lung cancer patients.
ISET® CTC-DNA for Early Stage Lung Cancer and Cancer Recurrence Detection.
In a collaboration with Professor Filippo Lococo from the Agostino Gemelli University and Policlinic Center of excellence in Rome, Italy, Rarecells is conducting a clinical study on early-stage operable lung cancer patients to comparatively assess the ISET® CTC-DNA and the ctDNA (standard extraction protocol) sensitivity for early cancer and cancer recurrence detection.